RxDoctor Payments Data

Hany Zaki, MD

Internal Medicine · Pasadena, CANPI 1376697151

Payments from drug & device makers

$10,888in general payments, 2019–2025

Across 40 payments — averaging $272.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Galderma Laboratories, L.p.$120
  • GSK$42
  • Novo Nordisk$40
  • Lilly USA, LLC$13

What the payments were for

  • Speaking & faculty fees$10,00092%
  • Food & beverage$8758%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)29$10,673
Galderma Laboratories, L.p.6$120
GSK2$42
Novo Nordisk2$40
Lilly USA, LLC1$13

How this compares

$10,888 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$55,892
Medicare patients
88
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$91,313
EliquisApixaban74$74,514
JanuviaSitagliptin Phosphate64$70,865
TrulicityDulaglutide36$48,087
OzempicSemaglutide39$36,474
EntrestoSacubitril/Valsartan27$31,983
FarxigaDapagliflozin Propanediol20$29,137
ProliaDenosumab16$27,214
XareltoRivaroxaban22$26,724
NexiumEsomeprazole Magnesium51$14,857
VascepaIcosapent Ethyl28$13,815
Spiriva HandihalerTiotropium Bromide20$12,664
Breo ElliptaFluticasone/Vilanterol17$11,697
Spiriva RespimatTiotropium Bromide17$10,571
MyrbetriqMirabegron12$9,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$13$48,08736 claims
Novo NordiskOzempic$40$36,47439 claims
GSKBreo Ellipta$42$11,69717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →